Ardelyx Inc (NASDAQ:ARDX) reported its fourth-quarter and full-year 2025 financial results after the market close on February 19, 2026, delivering a top-line revenue beat but falling short on the bottom line. The commercial-stage biopharmaceutical company’s results were met with a negative after-hours reaction from investors, with shares declining approximately 5.6% in extended trading.
Earnings and Revenue Versus Estimates
The company’s performance against Wall Street expectations presented a mixed picture. For the fourth quarter of 2025, Ardelyx reported total revenue of $125.2 million, surpassing the analyst consensus estimate of approximately $120.5 million. This represents a 7.8% revenue beat.
However, the earnings story was less favorable. The company reported a net loss of $407,000, or $0.00 per share, on a non-GAAP basis. This missed the analyst estimate for a small profit of $0.0129 per share. The miss on profitability appears to be the primary driver behind the negative after-market price action, overshadowing the stronger-than-expected sales performance.
The full-year 2025 results underscored the company's significant commercial growth, with total revenue reaching $407.3 million, a 22% increase over 2024.
Commercial Performance and Business Update
The earnings release highlighted the divergent trajectories of Ardelyx’s two flagship products, IBSRELA and XPHOZAH, both of which contain the same active ingredient, tenapanor.
- IBSRELA (for IBS-C): This product was the standout growth driver. Full-year 2025 revenue surged 73% to $274.2 million. Fourth-quarter revenue grew 61% year-over-year to $86.6 million. The company provided an ambitious outlook for this product, forecasting 2026 revenue between $410 and $430 million, which would represent at least 50% growth. Management also set a long-term target for IBSRELA to achieve $1 billion in annual revenue by 2029.
- XPHOZAH (for hyperphosphatemia in CKD patients on dialysis): Revenue for this product was $103.6 million for the full year 2025, a decline from $160.9 million in 2024. The company noted growth in total dispenses and an increased number of non-Medicare patients, but the year-over-year comparison reflects a challenging reimbursement environment addressed by its "patient-first" strategy. For 2026, Ardelyx expects XPHOZAH revenue between $110 and $120 million.
Financial Position and Pipeline Progress
Ardelyx ended the year with a solid cash position. Total cash, cash equivalents, and short-term investments stood at $264.7 million as of December 31, 2025, up from $250.1 million a year earlier.
The company is actively investing in its pipeline:
- It has launched a Phase 3 trial (ACCEL) to expand IBSRELA’s label to include patients with chronic idiopathic constipation (CIC), with topline results expected in the second half of 2027.
- A development program is underway for RDX10531, a next-generation NHE3 inhibitor, with plans to submit an Investigational New Drug application in the second half of 2026.
Outlook Versus Analyst Expectations
The company’s provided 2026 revenue guidance for its products offers a point of comparison with broader analyst models. Ardelyx’s combined product revenue guidance for IBSRELA and XPHOZAH ranges from $520 million to $550 million. This appears to be in line with, or slightly above, the current analyst consensus estimate for total 2026 sales of approximately $547.3 million, suggesting management’s confidence is aligned with external expectations.
Market Reaction and Conclusion
The market’s immediate negative reaction, as seen in the 5.6% after-hours decline, can be attributed to the earnings per share miss in the fourth quarter. While revenue growth, particularly for IBSRELA, remains exceptionally strong and the company’s forward guidance is robust, investors are likely focusing on the continued high costs of commercialization and pipeline investment that are pressuring near-term profitability. The net loss for the full year 2025 widened to $61.6 million from $39.1 million in 2024, driven by increased selling, general, and administrative (SG&A) and research and development (R&D) expenses.
In summary, Ardelyx’s quarter confirms its lead product, IBSRELA, is on a powerful growth trajectory with blockbuster potential. However, the path to sustained profitability remains a work in progress, and the market is punishing the short-term earnings disappointment despite the strong top-line performance and confident outlook.
For a detailed breakdown of future earnings estimates and historical performance, you can review more data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.